Concord Biotech logo

Concord Biotech financials: balance sheet, profit and loss, cash flow

NSE: CONCORDBIOBSE: 543960Pharmaceuticals & BiotechnologySmall Cap

Concord Biotech Limited · Face value ₹1 · Listed Aug 2023 · Issue price ₹741
Last close ₹1,268.50down ₹106.80 (7.77%)BSE ₹1,269.05

Share price at the NSE close on 28 Oct 2026. Previous close ₹1,375.30.

28 Oct: open ₹1,319.90, high ₹1,333.00, low ₹1,262.60

52-week range of traded prices to 28 Oct 2026
₹987.00Low, 2 Apr 2026₹1,615.00High, 20 Aug 2026
Market cap
₹13,271 Cr496th largest listed
P/E
46.98
P/B
6.39
Dividend yield
0.60%
ROE
14.5%
ROCE
15.9%
Debt to equity
0.00
Volume, NSE
3,80,22234.2% delivered

Concord Biotech's financial statements for the 3 years to Mar 2026, consolidated: the company and its subsidiaries together, with the half year to Sep 2026 after them. It had no borrowings at 30 Sep 2026.

3 years at a glance

₹ crore, years to March.Concord Biotech annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
1,0173086.2Mar 241,2003720.4Mar 251,0552590Mar 26
Peak revenue ₹1,200 Cr, year to Mar 2025; lowest ₹1,017 Cr, year to Mar 2024

Operating and net margin, per cent

  • Operating margin
  • Net margin
42.4%24.6%42.4%42.2%34.8%30.3%31.0%24.6%Mar 24Mar 25Mar 26

Results for the year to Mar 2026

Consolidated: the company and its subsidiaries together. ₹ crore.

From revenue to net profit

  1. Revenue1,055
  2. Materials and goods−246
  3. Employee costs−177
  4. Other expenses−265
  5. Operating profit367
  6. Depreciation−74
  7. Other income+52
  8. One-off items−3.3
  9. Finance costs−0.3
  10. Profit before tax342
  11. Tax−85
  12. Joint ventures+2.9
  13. Net profit259

What the company owns

  • Plant, investments and other assets₹1,033 Cr
  • Receivables₹460 Cr
  • Current investments₹402 Cr
  • Inventory₹326 Cr
  • Cash and bank₹14 Cr

What pays for it: net worth and liabilities

  • Net worth₹2,015 Cr
  • Other liabilities₹118 Cr
  • Owed to suppliers₹102 Cr

Profit and loss

Consolidated, ₹ crore, years to March. The last column is the twelve months to Sep 2026, the latest four quarters added.Concord Biotech quarterly results

₹ croreMar 2024Mar 2025Mar 2026Sep 2026Twelve monthsFiled 27 Oct
Revenue from operations1,0171,2001,0551,170
585694687766
Materials and goods bought229306246279
Employee costs123139177191
Other expenses233249265296
Operating profit before depreciation432506367404
Operating margin42.4%42.2%34.8%34.5%
Materials, % of revenue22.5%25.5%23.3%23.9%
Employee costs, % of revenue12.1%11.6%16.8%16.3%
Other expenses, % of revenue22.9%20.8%25.1%25.3%
Depreciation and amortisation54547475
Operating profit after depreciation378452293330
Other income34445248
Finance costs3100
Profit before one-off items and tax409496345378
One-off items00−3−3
Profit before tax409496342374
1041238595
Share of profit of joint ventures and associates3−130
308372259279
Other comprehensive income065545
Total comprehensive income308378314324
Net margin30.3%31.0%24.6%23.9%
Net margin without joint ventures and associates30.0%31.1%24.3%–

Balance sheet

Consolidated, ₹ crore, at 31 March. The last column is the half year to Sep 2026, after the latest full year: the balance sheet at its end.

₹ croreMar 2024Mar 2025Mar 2026Sep 2026Half yearFiled 27 Oct
1,5271,8132,0152,072
1,5271,8132,0172,076
Share capital10101010
Reserves1,5161,8022,0072,065
Belonging to outside owners of subsidiaries–0−2−4
Borrowings6000
142184169202
32375153
Total assets1,7012,0342,2352,327
8048999851,036
8961,1351,2501,291
Net debt−284−317−416−446
Borrowings are counted again inside the liabilities due within a year and after a year. Plant in use and plant being built are given for full years only.

Cash flow

Consolidated, ₹ crore, years to March. The last column is the half year to Sep 2026, after the latest full year: the cash flow over its six months.

₹ croreMar 2024Mar 2025Mar 2026Sep 2026Half year
265245267168
370354367222
−81−171−1429
Receivables−79−1717049
Inventories4−32−87−71
Payables−1122−911
Other working capital4101140
Tax paid−103−109−100−53
Capital spending861119560
Free cash flow180133172108
−155−160−143−93
−99−99−113−80
Dividends paid719211279
Shares bought back0000
Shares issued0000
Net change in cash12−1411−5
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only.

Per share

Consolidated, ₹ per share, years to March.Concord Biotech dividend history

₹ per shareMar 2024Mar 2025Mar 2026
Earnings per share₹29.45₹35.52₹24.78
Diluted earnings per share₹29.45₹35.52₹24.78
Dividend per share₹8.75₹10.70₹7.55
Book value per share₹145.93₹173.27₹192.81
Dividend payout29.7%30.1%30.3%
Shareholder yield0.4%0.5%1.1%
Market cap at the year end (₹ crore)15,91017,58210,654

Ratios

Consolidated, years to March.Concord Biotech PE ratio and valuation

RatioMar 2024Mar 2025Mar 2026
Revenue growth–18.0%−12.1%
Operating profit growth–17.3%−27.4%
Net profit growth–20.6%−30.2%
Earnings per share growth–20.6%−30.2%
20.2%22.3%13.6%
–2.1 pts−8.6 pts
From the net margin–0.4 pts−4.5 pts
From asset turnover–1.5 pts−4.1 pts
From borrowing–0.1 pts0.0 pts
Return on capital employed24.7%24.9%14.5%
Cash conversion86.2%65.8%103.0%
Interest cover148.1853.91,034.4
Debt to equity0.000.000.00
Receivable days125159159
Inventory days331286485
Payable days150135151
Cash conversion cycle, days306310493
Working capital days169193230
Asset turnover0.600.640.49
Assets per rupee of net worth1.111.121.11
Sales per rupee of plant1.781.521.34
Capital spending to depreciation1.602.041.28
Plant being built, % of plant in use37.0%6.3%9.9%

Growth and returns over 3, 5 and 10 years

Consolidated: the company and its subsidiaries together. Each window ends with the year to Mar 2026.

Return on assets, latest year
12.2%
Cash from operations against operating profit
72.6%
Measure3 years
Return on equity, average18.7%
Return on capital employed, average21.4%
Operating margin, average39.8%
Net margin, average28.6%
Asset turnover, average0.58
Cash conversion cycle, days, average370
Interest cover, average678.8
Debt to equity, average0.00

Where the cash came from and went

Consolidated: the company and its subsidiaries together. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ crore3 yearsLatest year
Cash from operations777267
Cash from investing−457−143
Cash from financing−311−113
Capital spending29295
Dividends paid275112
Shares bought back00
Shares issued for cash00
Borrowings raised00
Borrowings repaid310

Accounting checks

Consolidated, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2024Mar 2025Mar 2026
Piotroski score, out of 9Published threshold 3 points out of 9––6
Altman Z-scorePublished threshold 1.8158.0250.8131.93
Beneish M-scorePublished threshold −1.78–−2.00−2.58
Profit not backed by cash, % of assetsPublished threshold 10 per cent of average total assets–15.376.33
Cash from operations to profit, 3 yearsPublished threshold 0.7 times––0.83
Receivables growth less revenue growthOur threshold 0 percentage points–31.200.32
Inventory growth less cost-of-goods growthOur threshold 0 percentage points–−18.0555.76
Other current assets growth less revenue growthOur threshold 5 per cent of revenue–−2.713.09
Assets under construction, years of additionsOur threshold 2 years of additions–0.181.14
Effective tax ratePublished threshold 17.16 per cent25.5324.7925.00
Tax charged less tax paid, % of profitOur threshold 10 percentage points0.272.72−4.39
A threshold marked as ours has no published figure; it is the line we read the check against.

Credit ratings

An agency's view of the chance the company repays a borrowing on time, from AAA, the highest, down to D, in default.

DateAgencyBorrowing ratedRatingOutlookAmount, ₹ Cr
23 Sep 2026ICRA LimitedFund-based-Cash credit[ICRA]AA-Review, Re-affirmStable65
23 Sep 2026ICRA LimitedUnallocated limits-Unallocated limits[ICRA]AA-Review, Re-affirmStable25
23 Sep 2026ICRA LimitedNon-fund based-Others[ICRA]A1+Review, Re-affirm35
The latest rating on each borrowing. The agency's name opens its reasoning for the rating.